
Intra-Cellular Therapies: Tale of the Tape – Q4 Loss Surprises, Revenues Beat Estimates!
ITCI’s Q3 Loss: A Closer Look Intra-Cellular Therapies (ITCI) recently reported its third-quarter financial results, and the numbers didn’t quite meet the expectations of analysts. The biopharmaceutical company reported a loss of $0.16 per share, which was a bigger gap than the Zacks Consensus Estimate of a loss of $0.05. This represents a significant improvement…